Respiratory Syncytial Virus After CAR T-cell therapy: Risk Factors and Outcomes in a Multicenter Retrospective Cohort.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 41733325.
- Also identified by DOI 10.1093/cid/ciag052.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Among 667 CAR-T recipients, the 2-year cumulative incidence of RSV was 7%, with 29% of diagnosed cases progressing to LRTI. Older age and lymphopenia were associated with severity. Most infections (74%) occurred beyond day +100 (median 8 months). No RSV-attributable deaths occurred. Clinical vigilance is warranted, especially during RSV season.